TANDEM DIABETES CARE INC
For the period ended Dec 31, 2025. Filed Feb 19, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 19, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Tandem Diabetes Care, Inc. | |
| By: | /s/ John F. Sheridan |
| John F. Sheridan | |
| President, Chief Executive Officer and Director | |
| (Principal Executive Officer) |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints John F. Sheridan and Leigh A. Vosseller, and each of them individually, his and her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him and her and in his and her name, place, and stead, in any and all capacities, to sign any and all amendments to this Annual Report, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ JOHN F. SHERIDAN | President, Chief Executive Officer and Director (Principal Executive Officer) | February 19, 2026 |
| John F. Sheridan | ||
| /s/ LEIGH A. VOSSELLER | Executive Vice President, Chief Financial Officer and Treasurer (Principal Financial and Accounting Officer) | February 19, 2026 |
| Leigh A. Vosseller | ||
| /s/ SANDRA W. BEAVER | Director | February 19, 2026 |
| Sandra W. Beaver | ||
| /s/ MYOUNGIL CHA | Director | February 19, 2026 |
| Myoungil Cha | ||
| /s/ PEYTON R. HOWELL | Director | February 19, 2026 |
| Peyton R. Howell | ||
| /s/ JOAO PAULO FALCAO MALAGUEIRA | Director | February 19, 2026 |
| Joao Paulo Falcao Malagueira | ||
| /s/ KATHLEEN MCGRODDY-GOETZ | Director | February 19, 2026 |
| Kathleen McGroddy-Goetz | ||
| /s/ REBECCA B. ROBERTSON | Chair of the Board | February 19, 2026 |
| Rebecca B. Robertson | ||
| /s/ RAJWANT S. SODHI | Director | February 19, 2026 |
| Rajwant S. Sodhi | ||
| /s/ CHRISTOPHER J. TWOMEY | Director | February 19, 2026 |
| Christopher J. Twomey | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.